TACROLIMUS AND PRETRANSPLANT HIGH-DOSE R-ATG INDUCTION VS TACROLIMUS MONOTHERAPY AS TOLEROGENIC IMMUNOSUPPRESSION IN ADULT LIVER TRANSPLANTATION.AN OPEN LABEL, RANDOMISED, PROSPECTIVE AND CONTROLLED TRIAL. - TACATG

IVERSITY HOSPITALS ST LUC0 个研究点目标入组 100 人开始时间: 2006年9月11日最近更新: 2023年10月23日

适应症

试验速览

暂无简介。

•One hundred adult patients will be enrolled.
•1. The patient (male or female) must not be less than 15 years of age
•2. Post-mortem or living donor liver allograft recipients undergoing their first transplantation
•3. If female of childbearing potential, the patient must have practiced a medically approved form of contraception for a minimum of 30 days prior to study entry, and must continue to do so for the duration of the study treatment.
•4. The patient or his/her guardian must voluntarily sign an Ethics Committee-approved informed consent form for entry into this study after the contents of that document have been fully explained
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1) Patients undergoing liver allograft re-transplantation
•2) Patients who have undergone a previous organ transplantation
•3) Patients with advanced (stage III – IV – VICC) neoplastic disease.
•4) Patients with ABO incompatibility to the donor
•5) Patients with autoimmune hepatitis
•6) Patients who have received an investigational drug within 30 days of entry into this trial

发起方

IVERSITY HOSPITALS ST LUC